Tenax Therapeutics (TENX) Share-based Compensation (2010 - 2026)

Tenax Therapeutics has disclosed Share-based Compensation across 17 years of filings, most recently posting $23.9 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 294.62% year-over-year to $23.9 million; the TTM figure through Jun 2026 stood at $23.9 million (up 294.62% YoY), while the FY2025 annual figure was $19.2 million, up 25.25% from the prior year.
• Share-based Compensation came in at $23.9 million for Q2 2026 at Tenax Therapeutics, down from $26.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $26.5 million in Q1 2026 to a low of $646.0 in Q4 2023.
• Average Share-based Compensation over 5 years is $7.1 million, with a median of $2.6 million recorded in 2024.
• Year-over-year, Share-based Compensation dropped 4.86% in 2023 and jumped 204344.44% in 2025.
• Over 5 years, Share-based Compensation stood at $679.0 in 2022, then decreased by 4.86% to $646.0 in 2023, then surged by 150054.8% to $970000.0 in 2024, then soared by 393.81% to $4.8 million in 2025, then jumped by 398.96% to $23.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $23.9 million in Q2 2026, $26.5 million in Q1 2026, and $4.8 million in Q4 2025.